Results mixed on Merck's new painkiller (Associated Press)
13th Nov 2006, 14:52 GMT
The first published studies of Arcoxia, the drug that Merck & Co. hopes will take the place of its withdrawn painkiller Vioxx, are getting mixed reviews from doctors, some of whom say the results do not make a case for the medication's approval.
Results mixed on Merck's new painkiller (Associated Press) related news:
- Docs Give Merck Painkiller Acroxia Mixed Reviews — FOXNews.com
- Results Mixed on Merck's New Painkiller — LancasterOnline - Health
- Results mixed on Merck's new painkiller (AP) — Yahoo! News: Health News
- Results on Merck's new painkiller draw mixed reviews — azcentral.com | business
- Tests of new Merck painkiller criticized — baltimoresun.com - health & science
- Merck: New pain killer safer than Vioxx — Business and financial news - CNNMoney.com
- Merck says new drug is safer than Vioxx — Cardiology News from StratCenter.com
- Mixed reviews for Vioxx successor — MSNBC.com: Health
- Vioxx-Like Drug Gets Mixed Reviews — Dayton Daily News National Headlines
- Merck: Arcoxia heart risk same as Voltaren — United Press International - Health Business
Latest news from Yahoo! Health: Health News:
- Simple steps can speed heart attack care: study (Reuters)
- Hospitals want faster heart attack care (Associated Press)
- Diabetes threatens many of world's indigenous people (Reuters)
- Fast test catches heart blockages, U.S. study shows (Reuters)
- Children showing hardening of arteries -U.S. study (Reuters)
- Children showing hardening of arteries: U.S. study (Reuters)
- Two Canada professors win right to toke up at work (Reuters)
- Group gives advice on face transplants (Associated Press)
- Diabetes drug may cut heart risks: study (Reuters)
- Radioactive iodine linked to thyroid disease (Reuters)